The acquisition will expand Premaitha's market in Asia, enable it to develop new products, and strengthen its patent position in NIPT.
A hospital lab associated with Mahidol University in Thailand will now offer the firm's Iona test in that country and its neighbors.
By offering NIPT as a secondary screening test, the UK hopes to reduce the number of invasive diagnostic tests and associated miscarriages.
Premaitha said it has sold more than 17,000 of the tests, which is the focus of an ongoing patent-infringement suit, since its launch in early 2015.
During a case management conference last week, Premaitha said the EC's competition department contacted it regarding an investigation into Illumina and Sequenom.
A UK court accepted an application by Premaitha to include an antitrust claim in its defense, and has tentatively scheduled the trial for the summer of 2017.
The agreement marks the sixth Iona distribution deal Premaitha has signed with regional partners in recent months, including ones in France and India.
St. George's University Hospitals NHS Foundation Trust, which has been offering NIPT since last year, plans to double its capacity by the third quarter.
Visional Medical will begin offering the test, which estimates the risk of a fetus being affected by Down syndrome and other genetic conditions, in India.
The recommendation calls for NIPT to be initially offered to women deemed at high risk for trisomy 21, 13, or 18 after the initial screening test.
In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.
The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.
A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.
Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.